USFDA gives Ajanta Pharma final approval for migraine pain relief tablet

Ajanta Pharma has received a final approval for its generic version of acute migraine pain relief drug almotriptan malate tablets from the US health regulator.

The approval by the US Food and Drug Administration (USFDA) is for multiple strengths of 6.25 mg and 12.5 mg of the generic version of Janssen Pharmaceuticals' Axert tablets, Ajanta Pharma said in a BSE filing.

Ajanta Pharma USA Inc, a wholly-owned subsidiary of the company, is scheduled to launch the almotriptan malate tablets in the US shortly, it said.

Almotriptan tablet is a part of an "ever-growing portfolio" that the company has developed for the US market, the company added.

The USFDA has so far granted final approvals for eight abbreviated new drug applications (ANDAs) and two tentative approvals, it said, adding that an additional 16 ANDAs are under review.  

Indian markets are closed on March 7, Monday, on account of Mahashivratri.  

On Friday, the stock of Ajanta Pharma closed up 2.51% or Rs 34.20 at Rs 1397.20 per scrip on the BSE.